Decrease of FZD4 exon 1 methylation in probands from FZD4-associated FEVR family of phenotypic heterogeneity

Miaomiao Liu†, Jia Luo†, Huazhang Feng, Jing Li, Xiang Zhang, Peiquan Zhao* and Ping Fei*

Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Familial exudative vitreoretinopathy (FEVR) is an important cause of childhood blindness and is clinically characterized by phenotypic heterogeneity. FEVR patients harboring the same genetic mutation vary widely in disease severity. The purpose of this study was to explore non-genetic factors that regulate FEVR phenotypic heterogeneity. We detected methylation levels of 21 CpG sites located at the FZD4 exon 1 region of probands, asymptomatic/paucisymptomatic carriers and non-carriers from unrelated FZD4-associated FEVR families using bisulfite amplicon sequencing (BSAS). Our results showed reduced methylation level of FZD4 exon 1 in probands, suggesting that FZD4 exon 1 methylation level may be negatively linked with FEVR disease severity. It provided a new research direction for follow-up research, helping us better understand the complexity of the FEVR-causing mechanism.

KEYWORDS
familial exudative vitreoretinopathy (FEVR), the receptor frizzled-4 (FZD4), phenotypic heterogeneity, DNA methylation, epigenetics

Introduction

Familial exudative vitreoretinopathy (FEVR) is a clinically and genetically heterogeneous ophthalmic disorder characterized by incomplete retinal vascular development. The disease was first described in 1969 by Criswick and Schepens (1), and it is a major cause of vision loss in juveniles. Several sight-threatening complications are considered secondary to retinal avascularity, including retinal neovascularization and exudates, retinal fold and detachments, vitreous hemorrhage, and macular ectopia, ultimately leading to total blindness. The clinical appearance of FEVR varies considerably. The mildly affected patients may have only a small avascular area at the peripheral retina, which is visible only by fundus fluorescein angiography (FFA), while severely affected patients often registered as blind during infancy. With extensive fundus screening, we now realize that the prevalence of FEVR is much higher than we thought before (2). Therefore, it is imperative to study the mechanism underlying FEVR in order to seek for advanced therapy.
In the past decades, research on FEVR has mainly focused on genomics. At least 9 genes have been reported to cause FEVR: norrin cysteine knot growth factor NDP (NDP; MIM: 300658) (3); low-density lipoprotein receptor-related protein 5 (LRP5; MIM: 603506) (4); tetraspanin 12 (TSPAN12; MIM: 613138) (5); frizzled class receptor 4 (FZD4; MIM: 604579) (6, 7); kinesin family member 11 (KIF11; MIM:148760) (8, 9); zinc finger protein 408 (ZNF408; MIM: 616454) (10); catenin, β-1 (CTNNB1; MIM: 116806) (11, 12); jagged 1 (JAG1; MIM: 601920) (13); and catenin, α-1 (CTNNAL1; MIM:116805) (14). These gene mutations explain approximately 50% of FEVR cases. Mutations in six of the nine genes (FZD4, TSPAN12, NDP, LRP5, CTNNB1, and CTNNAL1) are related to the Norrin/ Wnt β-catenin signaling pathway, which coordinates retinal development and angiogenesis by regulating cell survival, differentiation, proliferation, and migration (15, 16). The NDP gene encodes the extracellular ligand Norrin, which binds specifically to the receptor/coreceptor (FZD4, LRP5 and TSPAN12) and forms a ligand-receptor complex. Upon activation of Norrin signaling, β-catenin translocates to the nucleus, binds to TCF/LEF (T cell factor/lymphoid-enhancing factor) and subsequently modulates gene expression (17–19). Mutations in CTNNAL1 induce overactivation of Norrin/β-catenin signaling and interrupt cell junctions (20, 21). The inheritance patterns of FEVR include autosomal dominant (AD), autosomal recessive (AR), and X-linked recessive (XL), and the severity of patients was determined by the highest stage of FEVR in either eye. Subjects with histories of oxygen inhalation and preterm birth were also excluded. All enrolled participants were diagnosed by ophthalmologist with expertise in FEVR.

Methods

Subjects

760 probands were recruited based on a clinical diagnosis of FEVR at the ophthalmology department of Xinhua hospital from May 2010 to August 2019. Next Generation Sequencing (NGS) revealed that 112 probands carried only FZD4 gene mutations, without other known FEVR-associated gene mutation. We further collected family history information of these 112 FZD4 Gene mutation probands. Finally, 10 FZD4-associated FEVR families met the following inclusion criteria were recruited. Each enrolled family contained at least one FZD4 proband (Staged 3–5), one asymptomatic/paucisymptomatic carrier of the mutant allele (clinically healthy or staged 1) and one non-carrier. Stage 2 individuals were excluded to maximize the phenotypic heterogeneity feature in our study design. Clinical staging was based on Trese’s 5-stage system (31) and the severity of patients was determined by the highest stage of FEVR in either eye. Subjects with histories of oxygen inhalation and preterm birth were also excluded. All enrolled participants were diagnosed by ophthalmologist with expertise in FEVR. All work was performed in accordance with the approved study protocol. Written informed consent was obtained from all the participants or their parents.

Analysis of FZD4 Rs10128621 single nucleotide polymorphisms

Cis-regulatory variants might also modify mutation penetrance and contribute to clinical heterogeneity (32). FZD4 rs10128621 SNP is the only known SNP which could affect FZD4 gene expression (33). We performed Sanger sequencing to analyze FZD4 rs10128621 SNP in our cohort. The primer sequences were as follows: 5′-ACCTTGGCTTCCTAAAGTGTTG-3′ (forward primer) and 5′-CTGCCGTAGAGACAGTAAAGA-3′ (reverse primer). The expected amplicon is 297 bp in length.
Bisulfite amplicon sequencing for methylation analysis

DNA methylation was analyzed by Bisulfite amplicon sequencing (BSAS). About 5 mL of peripheral blood samples were collected from each participant in a standard EDTA tube. Genomic DNA was extracted and purified using QIAamp DNA Mini kit. One hundred thirty microliter of CT Conversion Reagent was added to 300 ng purified DNA samples as per the manufacturer’s instructions. This process converted unmethylated cytosines (C) in CpG sites to uracil (U), whereas methylated C remained C. The primer sequences were as follows: 5’-TTTAGTTTGGGGTTTTTTGAGT-3’ (forward primer) and 5’-CTTTTCCTAAAAACTATCTCCTTC-3’ (reverse primer). PCR library was constructed using VAHTS Turbo DNA Library Prep Kit for Illumina and sequenced on a Miseq system (Illumina). Quality control was performed using FastQC v 0.11.2. Mapping and calling of the methylation levels were performed using bismark software and methylKit (R package 4.1.0), respectively.

Statistical analysis

Independent Samples T-test was used to pairwise compare the methylation differences among probands, carriers and non-carriers. Significant differences were determined as p < 0.05. Data analysis was performed using Graphpad 9.0.

Results

Characteristics of subjects

Thirty-four members of 10 FZD4-associated FEVR families were recruited in our study, including 11 FEVR probands, 12 asymptomatic/paucisympotomatic carriers of the same mutation, and 11 non-carriers of the mutant alleles. FEVR probands and family members were studied as a whole to best ensure similar genetic and environmental backgrounds. While FEVR probands had the most advanced ocular manifestations early in life, most of the family members carrying the same gene mutation were asymptomatic, only 4 carriers presented with Stage 1 FEVR. The mean age of probands, carriers and non-carriers were 35.1 ± 48.5 months (average ± standard deviation), 32.2 ± 12.2 years and 32.5 ± 14.8 years, respectively. Other than mutations in FZD4, no additional known FVR-associated mutation was found in these subjects. Family No. 2, 5, 8 (chr11:8665923 c.205C>T) and family No. 7, 10 (chr11:8665894-8666911 c.217_234del) shared the same mutation, respectively. The clinical details and genetic test results were summarized in Table 1. Fundus photographs and FFA of family No. 8 were presented in Figure 1.

Map of CpG island in the FZD4 exon 1 region

We confirmed the methylation of CpG islands in FZD4 using a genomic map of FZD4 (NM_012193.4). FZD4 is located on the negative strand of chromosome 11. Most of the CpG island (CpG:69) exists in the exon 1 region. Twenty-one CpG sites were identified from a fragment in the exon 1 region at 86,665,722–86,666,073 (Figure 2).

Methylation analysis of 21 CpG sites

Before DNA methylation, we performed Sanger sequencing to analyze FZD4 rs10128621 SNP in our cohort. Sanger sequencing results showed a complete consistency of G base. Our results did not support the role of FZD4 rs10128621 SNP in the phenotypic heterogeneity of our FEVR patients. (Supplementary Figure S1)

DNA methylation levels of 21 CpG sites identified above in probands and their family members were presented in Figure 3, except for the non-carrier of family No. 8, whose blood sample was not obtained due to data missing. At almost all tested CpG sites (19 out of 21), FEVR probands held the lowest average methylation level compared to carriers and non-carriers, except for CpG4 and CpG5, where probands had slightly higher methylation levels than carriers. At more than half of the CpG sites (12 out of 21), carriers held lower methylation levels than non-carriers. DNA methylation levels of probands were significantly lower than symptomatic/paucisymptomatic carriers in CpG14 (p = 0.0009), CpG15 (p = 0.0489) and CpG16 (p = 0.0320). DNA methylation levels of probands were significantly lower than non-carriers at CpG1 (p < 0.0001), CpG15 (p = 0.0371) and CpG13 (p = 0.0021). Overall, the results suggested probands had lower DNA methylation compared with carriers and non-carriers in FZD4 exon 1 region.

The methylation levels of these six significantly different CpG sites in each of the 10 FEVR families were shown in Figure 4. It showed that FEVR probands had lower methylation levels nearly in almost all cases. For example, at CpG14, probands in all 10 families had lower methylation levels. In addition, we noticed a negative correlation at CpG14 between methylation levels and disease severity within three families (No. 2, 5 and 8) that happened to carry the same mutation (chr11:8665923 c.205C>T). Proband from family No. 2 had the most advanced FEVR and the lowest methylation level at CpG14 compared to the rest. Similar negative correlations also existed for CpG15 and CpG16.
| Family ID | Gender | Age at diagnose /month | Disease stage (OD/OS) | Retinal folds (OD/OS) | Retinal detachment (OD/OS) | Others | Asymptomatic/paucisymptomatic | Non carrier | Genomic coordinate (hg19) | Exon | Nucleotide change | Zygosity |
|-----------|--------|------------------------|-----------------------|----------------------|---------------------------|--------|-----------------------------|-------------|--------------------------|-------|-----------------|-----------|
| 1         | M      | 42                     | 5/1                   | NA/No                | NA/No                     | OD corneal staphyloma      | Father   | N                         | Mother      | chr11-86662767 | Exon2     | c.1031dup        | het       |
| 2         | M      | 12                     | 3b/3a                 | NA                   | NA                        | Mother N                 | Mother   | N                         | Father      | chr11-86665923 | Exon2     | c.205C>T         | het       |
| 3         | F      | 12                     | 1/5                   | No/No                | No/Yes                    | OS disappearance of anterior chamber | Mother   | N                         | Father brother | chr11-86663328 | Exon2     | c.470T>C          | het       |
| 4         | M      | 29                     | 4a/4a                 | Yes/Yes              | Yes/Yes                   | Mother N                 | Father   | N                         | chr11-86663485 | Exon2        | c.313A>G       | het       |
| 5         | F      | 19                     | 5/1                   | NA                   | NA                        | Mother N                 | Father   | N                         | chr11-86665923 | Exon1        | c.205C>T       | het       |
| 6         | M      | 6                      | 1/5                   | No/Yes               | No/Yes                    | OS disappearance of anterior chamber | Father grandfather | 1 1 | Grandmother | chr11-86662513–86662516 | Exon2 | c.1282_1285del | het       |
| 7         | F      | 174                    | 1/5                   | No/Yes               | No/Yes                    | Mother I                 | Father   | I                         | chr11-86665894–86665911 | Exon1 | c.217_234del | het       |
| 8         | M      | 17                     | 5/0                   | Yes/No               | Yes/No                    | Father N                 | Mother   | N                         | chr11-86665923 | Exon1        | c.205C>T       | het       |
| 9         | M      | 5                      | 4a/0                  | Yes/No               | Yes/No                    | OD lens opacity           | Father   | I                         | chr11-86662817 | Exon2        | c.981G>A       | het       |
| 10        | M      | 16                     | 4a/3a                 | Yes/Yes              | Yes/Yes                   | Father brother 1          | Mother   | N                         | chr11-86665894–86665911 | Exon1 | c.217_234del | het       |

M, male; F, female; N, normal fundus; het, heterozygous; OD, right eye; OS, left eye; NA, not available.
FIGURE 1
Fundus photographs and fundus fluorescein angiography (FFA) of subjects from family No. 8. In this family, the c.205C>T mutation was detected in a 4-year-old proband boy and it was inherited from his father. OD and OS represented right eye and left eye, respectively. (A–D) Fundus and FFA photographs of FEVR proband. The proband suffered from monocular FEVR disease in the right eye and was staged 4A. Severe fibrous proliferation membrane connected the optic disc to the lens in the right eye, with subtotal retinal detachment and peripheral avascular zone. The left eye exhibited normal retinal appearance without prolonged filling time or leakage. (E,F) Fundus photographs of father. Fundus examination didn't reveal any FEVR presentation although the father carried the c.205C>T mutation. (G,H) Fundus photographs of mother. The mother was a non-carrier without any fundus abnormality.
Discussion

FEVR is a rare disease featured by peripheral retinal vascular abnormalities (19, 34). It is clinically characterized by phenotypic heterogeneity, suggesting that non-genetic factors are involved in disease etiology (2, 22, 23). Comparing the epigenetic features among FEVR family members with or without mutation would provide important information regarding epigenetic factors which could contribute to phenotypic heterogeneity. DNA methylation is a widely studied epigenetic modification type. Increasing number of evidence supported the role of DNA methylation in modulating the phenotypic expression of diseases (35–37). For example, Coppede et al. found that the increase of global DNA methylation might contribute to disease manifestation in amyotrophic lateral sclerosis (ALS) carriers of not fully penetrant SOD1 mutations (38). DNA methylation at promoter CpG islands (CGI) of Wnt pathway genes showed a significant association with progression-free survival in ovarian tumor patients (39). Although little is known about FEVR disease, altered DNA methylation has been demonstrated in many other vitreoretinopathy diseases such as age-related macular degeneration (AMD), proliferative vitreoretinopathy (PVR), and diabetic retinopathy (DR). Therefore, we hypothesized that DNA methylation changes might play a role in FEVR phenotypic heterogeneity.

Up to date, at least 9 genes have been reported to cause FEVR. In previous studies, we and others showed that with FZD4 mutations accounting for the greatest proportion of FEVR in Chinese population (23, 40, 41). The FZD4 gene encodes a 537–amino acid protein, which functions as a receptor of the Wnt signaling pathway (42). According to our previous work, more than half (51.43%) in the FZD4 group were identified asymmetry, suggesting FZD4 mutations might initiate the most diverse and asymmetric phenotypes (22). Previous study suggested epigenetic modifications might involve
FIGURE 3
The graph showed methylation levels of 21 tested CpG sites. The horizontal axis represented the position of CpG sites and the vertical axis represented percentage of methylation. Blue, orange and green points respectively indicated to 11 FEVR probands, 12 carriers and 11 non-carriers. Box plot data represented range (error bars), median (horizontal line), quartile values (box) and outliers (dots). Median methylation levels of probands, carriers and non-carriers were compared in pair using student’s t-test. DNA methylation levels of CpG1, CpG9 and CpG13 were significantly different between probands and non-carriers. DNA methylation levels of CpG14, CpG15 and CpG16 were significantly different between probands and carriers. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

FIGURE 4
The figure above showed methylation levels at six significantly different CpG sites of 10 FEVR families. The horizontal axis represented family ID and the vertical axis represented the methylation level of specific CpG site. (A–C) DNA methylation levels of CpG1, CpG9 and CpG13 were significantly different between probands and non-carriers. Yellow and blue points indicated to probands and non-carriers, respectively. (D–F) DNA methylation levels of CpG14, CpG15 and CpG16 were significantly different between probands and carriers. Yellow and green points indicated to probands and carriers, respectively.
in the developing fetal retina which caused high asymmetric FZD4 gene expression (43). Therefore, it is important to study non-genetic factors underlying FZD4-associated FEVR phenotypic heterogeneity.

Bisulfite sequencing was first reported by Frommer et al. in (44). The bisulfite treated-DNA is amplified by PCR, and then the cloning and sequencing results of PCR products are used to determine whether the CpG site was methylated. This method has been recognized as one of the most powerful approaches to investigate DNA methylation patterns due to its reliable results, high accuracy and high sensitivity. It allows the determination of methylation at a single-cytosine resolution and has become the "gold standard" for DNA methylation detection (45, 46).

The current study aimed to access evidence of a link between FEVR phenotypic heterogeneity and FZD4 methylation status. We focused on 10 unrelated clinically heterogeneous FEVR families carrying only FZD4 gene mutation. In this study, our goal was to investigate whether there was a difference in methylation levels between probands at severe FEVR stage and parents with mild phenotype. Stage 1 FEVR has only peripheral avascular zone seen by fluorescein fundus angiography. Patients with stage 1 FEVR may be stable for decades without any progression. Therefore, we grouped asymptomatic and stage 1 carriers together. Our data indicated a negative correlation between DNA methylation in FZD4 exon 1 region and FEVR severity, which requires further validation. Among the six significantly different CpG sites, four sites (CpG13, CpG14, CpG15 and CpG16) were adjacent, suggesting that this region might play an important and unique role in the regulation of FZD4 expression. Although the CpG9 of Family No. 9 and No.10 are obviously different, the probands still had the lowest average methylation level of the three groups and non-carriers had the highest average methylation level when these two families were eliminated. Our study suggests that changes in DNA methylation might contribute to the severity in FZD4-associated FEVR patients. The function of intragenic DNA methylation hasn’t been well recognized. Brenet et al. found that DNA methylation at the first exon is tightly linked to transcriptional silencing (47), while others believed that the methylation in the body of genes can actually activate gene transcription (48, 49). Although it remains controversial, given that altered methylation of a specific CpG site might be enough to change gene expression (50), FEVR probands with reduced DNA methylation are highly likely to undergo altered gene expression, thus causing different degrees of disease severity.

This study is limited by the number of FEVR families enrolled. For 5 mutations analyzed here, only one family was found for each mutation. Alternatively, we took the approach of comparing the average overall methylation level in probands, carriers and non-carriers, which could have masked the effect of specific mutation on DNA methylation. In addition, age may be an independent factor in the methylation level. However, in this study, after excluding the “grandmother” and “grandfather” subjects in family 6, the probands still had the lowest average methylation level among the three groups, which is in line with our conclusion. What’s more, we do not have RNA samples from our patients to validate the expression of FZD4. Future study with larger sample size is needed to validate our findings. Nevertheless, our results provided a new mechanism potentially responsible for phenotypic heterogeneity amongst FEVR patients.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Institutional Review Board of Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

ML and JLu are responsible for conceptualization, methodology, software, investigation, and writing original draft. HF is responsible for clinical data collection and writing. JLi and XZ are responsible for software and writing review. PF and PZ are responsible for supervision, writing review and funding acquisition. All authors contributed to the article and approved the submitted version.

Funding

This research was supported by Grant 81770963 from National Natural Science Foundation of China (to FP) and Grant 2018YFA0800801 from National Key Research and Development Program of China (to LJ).

Acknowledgments

The authors thank all the patients and their family members for their participation.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.976520/full#supplementary-material
31. Wang F, Zhang S, Wen Y, Wei Y, Yan H, Liu H, et al. Revealing the architecture of genetic and epigenetic regulation: a maximum likelihood model. *Brief Bioinform.* (2014) 15:1028–43. doi: 10.1093/bib/bbt076

32. Castel SE, Cervera A, Mohammadi P, Aguet F, Reverte F, Wolman A, et al. Modified penetrance of coding variants by cis-regulatory variation contributes to disease risk. *Nat Genet.* (2018) 50:1327–34. doi: 10.1038/s41588-018-0192-y

33. Gilmour DF. Familial exudative vitreoretinopathy and related retinopathies. *Eye (Lond.)* (2015) 29:1–14. doi: 10.1038/eye.2014.70

34. Quiñonez-Silva G, Dávalos-Salas M, Recillas-Targa F, Ostrosky-Wegman P, Aranda DA, Benítez-Bribiesca L. Monoallelic germline methylation and sequence variant in the promoter of the RB1 gene: a possible constitutive epimutation in hereditary retinoblastoma. *Clin Epigenetics.* (2016) 8:1. doi: 10.1186/s13148-015-0167-0

35. Pizzolo F, Friso S, Morandini F, Antoniazzi F, Zaltron C, Udali S, et al. Apparent mineralocorticoid excess by a novel mutation and epigenetic modulation by HSD11B2 promoter methylation. *J Clin Endocrinol Metab.* (2015) 100:E1234–41. doi: 10.1210/jc.2015-1760

36. Coppedé F, Stoccoro A, Mosca L, Gallo R, Tarlazzini C, Lunetta C, et al. Increase in DNA methylation in patients with amyotrophic lateral sclerosis carriers of not fully penetrant SOD1 mutations. *Amyotroph Lateral Scler Frontotemporal Degener.* (2018) 19:93–101. doi: 10.1080/21678421.2017.1367401

37. Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, et al. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. *Clin Cancer Res.* (2011) 17:4052–62. doi: 10.1158/1078-0432.CCR-10-3021

38. Li Y, Peng J, Li J, Zhang Q, Li J, Zhang X, et al. The characteristics of digenic familial exudative vitreoretinopathy. *Graefe’s Arch Clin Exp Ophthalmol.* (2018) 256:2149–56. doi: 10.1007/s00417-018-4076-8

39. Seo SH, Yu YS, Park SW, Kim JH, Kim HK, Cho SI, et al. Molecular Characterization of FZD4, LRP5, and TSPAN12 in Familial Exudative Vitreoretinopathy. *Invest Ophthalmol Vis Sci.* (2015) 56:5143–51. doi: 10.1167/iovs.14-15680

40. Zhang K, Harada Y, Soo T, Shu D, Rajendran A, Tawsany K, et al. An essential role of the cysteine-rich domain of FZD4 in Norrin/Wnt signaling and familial exudative vitreoretinopathy. *J Biol Chem.* (2011) 286:10219–5. doi: 10.1074/jbc.M110.194399

41. Aldiri I, Xu B, Wang L, Chen X, Hiler D, Griffla L, et al. The dynamic epigenetic landscape of the retina during development, reprogramming, and tumorigenesis. *Neuron.* (2017) 94:550–68.e10. doi: 10.1016/j.neuron.2017.04.022

42. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc Natl Acad Sci U S A.* (1992) 89:1827–31. doi: 10.1073/pnas.89.5.1827

43. Baylin SB, Schumann U, Shafrak A, Guarnacci M, Clark SJ, Preiss T. Target-specific profiling of RNA m(5)C methylation level using ampiclon sequencing methods. *PLoS ONE.* (2022) 2404:375–92. doi: 10.1073/pnas.1900418"